Gradient Denervation Technologies Appoints Stanton Rowe
Gradient Denervation Technologies, a forward-thinking medical device enterprise, has recently brought Stanton Rowe on board. This appointment marks a significant step as the company aims to enhance its efforts in creating innovative solutions for patients suffering from pulmonary hypertension.
Stanton Rowe's Impressive Background
Stanton Rowe is well-regarded in the medical technology vein, reflecting extensive experience in delivering clinically beneficial innovations. His previous roles include being the Chief Scientific Officer at Edwards Lifesciences and co-founding Percutaneous Valve Technologies, where he played a critical role in developing the first transcatheter aortic valve replacement device. His deep expertise in medical technology is viewed as a strong asset for Gradient Denervation Technologies.
The Expansion of the PreVail-PH2 Early Feasibility Study
Gradient Denervation Technologies also announced a significant development with the FDA's approval to expand the PreVail-PH2 Early Feasibility Study. The research focuses on patients with WHO Group 2 Pulmonary Hypertension. With a strong commitment to medical advancements, Gradient is actively enrolling participants and guiding clinical centers equipped with expertise in managing both heart failure and pulmonary hypertension.
The Exciting Future for Gradient Denervation
Joining the company, Rowe expresses his enthusiasm about contributing to a project he believes has the potential to transform patient care. "I'm very excited to join Gradient and work with the company to bring this technology to patients," he stated, emphasizing the promising early results from pulmonary denervation.
The Vision Shared by the Leadership
Gradient Denervation Technologies' CEO Martin Grasse remarked on the importance of this phase for the organization, expressing optimism about leveraging Rowe's experiences to navigate the road ahead. This collaborative spirit is crucial for the company's expansion efforts and technological advancements.
About Gradient Denervation Technologies
Gradient is focused on developing cutting-edge minimally invasive devices tailored to treat pulmonary hypertension in heart failure patients. The company relies on valuable intellectual property stemming from Stanford University, reinforcing its position in the medical field. However, it's essential to note that Gradient's device is currently for investigational use only and is not yet approved for commercial availability.
Media Contact Martin Grasse Chief Executive Officer Gradient Denervation Technologies info@gradientdenervation.com
Frequently Asked Questions
What is the role of Stanton Rowe at Gradient Denervation Technologies?
Stanton Rowe has been appointed to the board of directors, bringing his extensive experience in medical technology to the company.
What is the PreVail-PH2 Early Feasibility Study?
It's a clinical study approved by the FDA focusing on patients with WHO Group 2 Pulmonary Hypertension, assessing the safety and efficacy of Gradient's device.
What type of device is Gradient developing?
Gradient is developing a minimally invasive catheter system aimed at treating pulmonary hypertension in patients with heart failure.
Where does Gradient derive its intellectual property?
The company's technology is built upon intellectual property developed at Stanford University.
Is Gradient's device commercially available?
Currently, Gradient's device is under investigation and is not approved for commercial use.
